Biodistribution in tumour-bearing mice of two 90y-labelled biotins using three-step tumour targeting

Nuclear Medicine Communications

Volumn 18, Issue 2, 1997, Pages 176-182

  Chinol, Marco ^a   Paganelli, G ^a   Sudati, F ^b   Fazio, F ^b   Meares, C ^c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN DERIVATIVE; BIOTIN DOTA Y 90; BIOTIN PENTETATE Y 90; BIOTIN Y 90; MONOCLONAL ANTIBODY Y 90; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; PHARMACOKINETICS; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT;

EID: 0030954927     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199702000-00014     Document Type: Article

References (41)

1. Wessels BW, Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 1984; 11: 638-644.
2. Chinol M, Hnatowich DJ. Generator-produced yttrium-90 for radioimmunotherapy. J Nucl Med 1987; 28: 1465-1470.
3. Montravadi VP, Spigos DG, Tan WS et al. Intraarterial yttrium-90 in the treatment of hepatic malignancy. Radiology 1982; 142: 783-786.
4. Stewart JSW, Hird V, Snook D et al. Intraperitoneal yttrium-90 labeled monoclonal antibody in ovarian cancer. J Clin Oncol 1990; 8: 1941-1950.
5. Sundberg MW, Meares CF, Goodwin DA et al Chelating agents for the binding of metal ions to macromolecules. Nature 1974; 250: 587-588.
6. Sundberg MW, Meares CF, Goodwin DA et al. Selective binding of metal ions to macromolecules using bifunctional analogs of EDTA. J Med Chem 1974; 17: 1304-1307.
7. Krejcarek GE, Tucker KL. Covalent attachment of chelating groups to macromolecules. Biochem Biophys Res Commun 1977; 77: 581-585.
8. Hnatowich DJ, Layne WW, Childs RL et al. Radioactive labeling of antibody: A simple and efficient method. Science 1983; 220: 613-615.
9. Paik CH, Ebbert MA, Murphy PR et al. Factors influencing DTPA conjugation with antibodies by cyclic DTPA anhydride. J Nucl Med 1983; 24: 1158-1163.
10. Meares CF, Goodwin DA, Leung CS-H et al. Covalent attachment of metal chelates to proteins: The stability in vivo and in vitro of the conjugate of albumin with a chelate of n, indium. Proc Natl Acad Sci USA 1976; 73: 3803-3806.
11. Scheinberg DA, Strand M, Gansow O. Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science 1982; 215: 1511-1513.
12. Hart FA. Scandium, yttrium, and the lanthanides. In: Wilkinson G, ed. Comprehensive coordination chemistry. Oxford: Pergamon Press, 1987: 1059-1127.
13. Cossy C, Barnes AC, Enderby JE et al. The hydration of Dy3+ and Yb3+ in aqueous solution: A neutron scattering first order difference study. J Chem Phys 1989; 90: 3254-3260.
14. Jowsey J, Rowland RE, Marshall JH. The deposition of the rare earths in bone. Radiation Res 1958; 8: 490-501.
15. O’Mara RE, McAfee JG, Subramanian G. Rare earth nuclides as potential agents for skeletal imaging. J Nucl Med 1968; 10: 49-51.
16. Rowlinson G, Snook D, Stewart S et al. Intravenous EDTA to reduce bone uptake of Y-90 following Y-90 labeled antibody administration. Br J Cancer 1989; 59: 322.
17. Meares CF, McCall MJ, Reardan DT et al. Conjugation of antibodies with bifunctional chelating agents: Isothiocya-nate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 1984; 142: 68-78.
18. Brechbiel MW, Gansow OA, Atcher RW et al. Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA: Antibody labeling and tumor-imaging studies. Inorg Chem 1986; 25: 2772-2781.
19. Kozak RW, Raubitschek A, Mirzadeh S et al. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: Critical factors in determining in vivo survival and toxicity. Cancer Res 1989; 49: 2639-2644.
20. Washburn LC, Sun TTH, Lee Y-CC et al. Comparison of five bifunctional chelate techniques for 90Y-labeled monoclonal antibody CO 17-1A. Nucl Med Biol 1991; 18: 313-321.
21. Riesen A, Zehnder M, Kaden TA. Synthesis, properties, and structures of mononuclear complexes with 12-and 14-membered tetraazamacrocycle-N, N', N, N-tetraacetic acids. Helv Chim Acta 1986; 69: 2067-2073.
22. Moi MK, Meares CF. The peptide way to macrocyclic bifunctional chelating agents: Synthesis of 2-(p-nitroben-zyl)-l, 4, 7, 10-tetraazacyclododecane-N, AT, N, N'-tetra-acetic acid and study of its yttrium (III) complex. J Am Chem Soc 1988; 110: 6266-6267.
23. Cox JPL, Craig AS, Helps IM et al. Synthesis of C-and N-functionalised derivatives of 1,4,7-triazacyclonon-ane-l, 4, 7-triyltriacetic acid (NOTA), 1, 4, 7, 10-tetra-azacyclodode-cane-1, 4, 7,10-tetrayltetra-acetic acid (DOTA), and diethy-lenetriaminepenta-acetic acid (DTPA): Bifunctional complexing agents for the derivatisation of antibodies. J Chem Soc Perkin Trans 1990; 1: 2567-2576.
24. Deshpande SV, DeNardo SJ, Kukis DL et al. Yttrium-90-lab-eled monoclonal antibody for therapy: Labelling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990; 31: 473-479.
25. Harrison A, Walker CA, Parker D et al. The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates. Nucl Med Biol 1991; 18: 469-476.
26. Goodwin DA. Pharmacokinetics and antibodies. J Nucl Med 1987; 28: 1358-1362.
27. Goodwin DA, Meares CF, McCall MJ et al. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 1988; 29: 226-234.
28. Goodwin DA. Tumor pretargeting: Almost the bottom line. J Nucl Med 1995; 36: 876-879.
29. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987; 28: 1294-1302.
30. Paganelli G, Magnani P, Zito F et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991; 51: 5960-5966.
31. Paganelli G, Belloni C, Magnani P et al. Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur J Nucl Med 1992; 19: 322-329.
32. Paganelli G, Chinol M, Grana C et al. Optimization of the three-step pretargeting approach for diagnosis and therapy in cancer patients. J Nucl Med 1995; 36 (suppl. 5): 225 P.
33. Gasparini M, Ripamonti M, Seregni E et al. Tumor imaging of colorectal carcinoma with an anti-CEA monoclonal antibody. Int J Cancer 1988; 2 (suppl.): 81-84.
34. Siccardi AG, Buraggi GL, Callegaro L et al. Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab')2 fragments of an anti-carcinoembryonic antigen monoclonal antibody: A multicenter study. Cancer Res 1989; 49: 3095-3103.
35. Kosmas C, Snook D, Gooden CS et al. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmu-noconjugates for imaging and therapy. Cancer Res 1992; 52: 904-911.
36. Paganelli G, Magnani P, Meares CF et al. Antibody guided therapy of CEA positive tumors using biotinylated monoclonal antibodies, avidin and 90Y-DOTA-biotin: Initial evaluation. J Nucl Med 1993; 34 (suppl. 5): 94 P.
37. Deshpande SV, DeNardo SJ, Meares CF et al. Effect of different linkage between chelates and monoclonal antibodies on levels of radioactivity in the liver. Nucl Med Biol 1989; 16: 587-597.
38. Haseman MK, Goodwin DA, Meares CF et al. Metabolizable lnIn-chelate conjugated anti-idiotype mono-clonal antibody for radioimmunodetection of lymphoma in mice. Eur J Nucl Med 1986; 12: 455-460.
39. Jones PL, Brown BA, Sands H. Uptake and metabolism of 111 In-labeled monoclonal antibody B6.2 by the rat liver. Cancer Res 1990; 50 (suppl.): 825s-856s.
40. Virzi F, Fritz M, Rusckowski M et al New indium-111 labeled biotin derivatives for improved immunotargeting. Nucl Med Biol 1991; 18: 719-726.
41. Su F-M, Gustavson LM, Axworthy DB et al. Characterization of a new Y-90 labeled DOTA-biotin for pretargeting. J Nucl Med 1995; 36 (suppl. 5): 154 P.